A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Imitrex Indications, Dosage, Storage, Stability - Sumatriptan Succinate (intranasal)
Imitrex Indications, Dosage, Storage, Stability - Sumatriptan Succinate (intranasal)
INDICATIONS
Sumatriptan nasal spray
is indicated for the acute
treatment of migraine
attacks with or without aura
in adults.
Sumatriptan nasal spray
is not intended for the prophylactic
therapy of migraine
or for use in the management of hemiplegic
or basilar migraine
(see CONTRAINDICATIONS
).
Safety and effectiveness
of sumatriptan nasal spray
have not been established for cluster
headache, which is present
in an older, predominantly male population.
DOSAGE AND ADMINISTRATION
In controlled clinical
trials, single doses of 5, 10, or 20 mg
of sumatriptan nasal spray administered into one nostril
were effective for the acute treatment of migraine
in adults. A greater proportion of patients had headache response
following a 20-mg dose
than following a 5- or 10-mg dose
(see CLINICAL STUDIES).
Individuals may vary in response
to doses of sumatriptan nasal
spray. The choice of dose should therefore be made on an individual
basis, weighing the possible benefit of the 20-mg dose
with the potential
for a greater risk of adverse
events. A 10-mg dose may
be achieved by the administration
of a single 5-mg dose in
each nostril. There is evidence
that doses above 20 mg do
not provide a greater effect
than 20 mg.
If the headache returns,
the dose may be repeated
once after 2 hours, not to exceed a total daily dose
of 40 mg. The safety of treating an average of more than four headaches
in a 30-day period has
not been established.
HOW SUPPLIED
Store between 36-86°F (2-30°C).
Protect from light.
PRODUCT LISTING
|
|
| 1's |
Imitrex Statdose, Glaxo Wellcome
|
00173-0479-00
|
|
|
| 6's |
Imitrex Nasal, Glaxo Wellcome
|
00173-0524-00
|
|
|
| 6's |
Imitrex Nasal, Glaxo Wellcome
|
00173-0523-00
|
|
|
| 1's |
Imitrex Statdose, Glaxo Wellcome
|
00173-0478-00
|
| 5's |
|
00173-0449-02
|
top
